Literature DB >> 12817156

Improving the chance of recovery from the short- and long-term consequences of depression.

Hans-Jürgen Möller1, Koen Demyttenaere, Emilio Sacchetti, A John Rush, Stuart A Montgomery.   

Abstract

Major depressive disorder (MDD) is a common, chronic disorder that requires long-term management. Although effective treatments are available, MDD frequently remains undiagnosed. Furthermore, once recognized, treatment duration and dosage are often inadequate and adherence to medication is often poor. However, adequate acute phase treatment of MDD is essential to reduce symptomatology, and improve quality of life and the clinical course. After remission, treatment should be continued for 4-9 months to consolidate the remission and prevent relapse. For patients who do not respond adequately to their initial antidepressant therapy, switching or augmentation of therapy may be necessary. Many patients suffer residual symptomatology, even when classified as being in remission. In addition to the suffering and impairment that this causes, residual symptomatology is associated with a high rate of relapse. Clinicians should strive to achieve asymptomatic recovery both in terms of core symptomatology and psychosocial disability. This requires appropriate treatment at therapeutic doses for a sufficient duration; education and support to promote patient compliance with treatment; and regular monitoring and prompt intervention for patients with symptoms that persist even at subsyndromal levels. In conclusion, there remains considerable scope for improving the identification, treatment and management of patients with MDD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12817156     DOI: 10.1097/00004850-200307000-00004

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  4 in total

1.  Utility of self-reported sleep disturbances as a marker for major depressive disorder (MDD): findings from the World Mental Health Japan Survey 2002-2006.

Authors:  Shuntaro Ando; Norito Kawakami
Journal:  Psychiatry Res       Date:  2012-02-28       Impact factor: 3.222

Review 2.  The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research.

Authors:  Patrick E McKnight; Todd B Kashdan
Journal:  Clin Psychol Rev       Date:  2009-02-07

Review 3.  Somatic symptoms in depression.

Authors:  Hans-Peter Kapfhammer
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

4.  The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder.

Authors:  Maurizio Pompili; Paola Venturini; Marco Innamorati; Gianluca Serafini; Ludovica Telesforo; David Lester; Roberto Tatarelli; Paolo Girardi
Journal:  Neuropsychiatr Dis Treat       Date:  2011-05-06       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.